Treatment of Acute Lymphoblastic Leukemia in Children

Completed · Phase 3

Conditions studied: Acute Lymphoblastic Leukemia

In brief

The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well as from laboratory research.

Key facts

Study ID

NCT00165178

Run by

Dana-Farber Cancer Institute

People needed

498

Starts

2000-09-01

Expected to finish

2011-05-01

Last updated by the study team

2013-04-25

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Acute lymphoblastic leukemia excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14) (q24;q32), t(8;22) or t(2;8)
• Age > 12 months but less than 18 years

You may not qualify if…

• Prior therapy except, 1 week of steroids, or emergent radiation therapy to the mediastinum
• Known HIV positive

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.